Mexico Launches ambitious Winter Vaccination campaign Targeting 50.5 Million
Mexico is embarking on one of its most extensive public health initiatives in a decade with the launch of the National Winter Vaccination Campaign 2025-2026.The program aims to administer over 50.5 million doses against seasonal influenza, COVID-19, and pneumococcus between October 2025 and April 2026, prioritizing vulnerable populations including children under five, older adults, pregnant women, healthcare workers, and individuals with comorbidities.
A Multi-Pronged Approach to Winter Health
The campaign, coordinated by the National Center for Child and Adolescent Health (CENSIA), seeks to alleviate pressure on hospitals and prevent severe complications during the winter respiratory virus season. A senior official stated that consolidating simultaneous vaccination is now considered an “essential public policy” for the nation. With a target coverage rate of 95% and a commitment to national digital monitoring, the initiative aims to bolster collective immunity as Mexico navigates the post-pandemic epidemiological landscape.
Vaccine Distribution and Timelines
Secretary of Health, David Kershenobich Stalnikowitz, announced the plan includes 35.4 million influenza doses, 10.9 million COVID-19 doses, and 4.2 million pneumococcal doses. All institutions within the National Health System – including IMSS, ISSSTE, PEMEX, SEDENA, SEMAR, and IMSS-Bienestar – will participate in the rollout, operating under CENSIA’s technical guidance.
State Vaccination Councils (COEVAS) have been tasked with achieving 70% progress by December 31st and full coverage by the campaign’s conclusion in April 2026. Priority will be given to ensuring adequate coverage within both rural and urban communities. The campaign emphasizes avoiding missed vaccination opportunities,ensuring all eligible individuals receive the appropriate vaccine during healthcare visits. Success, according to official documents, hinges on robust logistics encompassing cold chain management, timely distribution, and active community engagement.
Updated Influenza Vaccine Offers Broad Protection
The seasonal influenza vaccine for this season is a quadrivalent,inactivated formulation updated in accordance with the World Health Organization (WHO) recommendations for the 2025-2026 northern hemisphere season. This updated vaccine provides expanded protection against both type A and B viruses, including the most recent variants circulating in North America and Europe. Administered intramuscularly in a 0.5 mL dose, the influenza vaccine is primarily targeted towards children aged 6 to 59 months, older adults, pregnant women, and individuals with chronic conditions like diabetes.
Pneumococcal Vaccine to Combat Childhood Illness
The 20-valent pneumococcal conjugate vaccine will be administered to children under five, a demographic particularly vulnerable to severe respiratory infections. Pneumococcal disease is a leading cause of childhood mortality in Latin America, responsible for the majority of pneumonia and meningitis cases in children under five. Studies from the CDC and the European Medicines Agency (EMA) confirm the 20-valent vaccine’s efficacy of over 90% against invasive strains and a high safety profile.
Streamlined vaccination and Digital monitoring
Technical guidelines for 2025-2026 authorize the simultaneous administration of all three vaccines, provided a minimum distance of 2.5 to 5 cm is maintained between injection sites. This approach aims to optimize resources, reduce healthcare visits, and enhance operational efficiency. Federal entities will deploy mobile brigades, semi-fixed locations, and vaccination sessions in hospitals, schools, and community centers to ensure extensive coverage for at-risk groups.
Progress will be tracked through the SISCENSIA platform,enabling real-time monitoring,traceability,and transparency in dose administration and reporting of any potential adverse events following immunization (ESAVI). The Ministry of Health will also strengthen epidemiological surveillance and impact evaluation, measuring reductions in infection, hospitalization, and respiratory mortality rates during peak viral circulation.
A Landmark Initiative for Public Health
The national Winter Vaccination Campaign 2025-2026 represents a significant milestone for mexican public health, distinguished by its scale, comprehensive focus on prevention, equity, and health technology. Beyond the numbers, the campaign seeks to rebuild public trust in vaccination and foster a culture of prevention, crucial for strengthening the national health system. If successful, Mexico could possibly reduce hospitalizations for respiratory diseases by up to 40% and prevent thousands of avoidable deaths. With its model of simultaneous immunization, data digitization, and international scientific backing, the country is positioning itself as a regional benchmark for integrated seasonal vaccination strategies.
